Author/Editor		Jezeršek Novaković, Barbara
Title		Checkpoint inhibitors in Hodgkin¼s lymphoma
Type		članek
Vol. and No.		Letnik 96, št. 4
Publication year		2016
Volume		str. 335-343
ISSN		0902-4441 - European journal of haematology
Language		eng
Abstract		Hodgkin lymphoma is unusual among cancers in that it consists of a small number of malignant Hodgkin Reed-Sternberg cells in a sea of immune system cells, including T cells. Most of these T cells are reversibly inactivated in different ways and their reactivation may induce a very strong immune response to cancer cells. One way of reactivation of T cells is with antibodies blocking the CTLA-4 and especially with antibodies directed against PD-1 or the PD-L1 ligand thereby reversing the tumor-induced downregulation of T cell function and augmenting antitumor immune activity at the priming (CTLA-4) or tissue effector (PD-1) phase. Immune checkpoint inhibitors have been evidenced as an additional treatment option with substantial effectiveness and acceptable toxicity in heavily pretreated patients with Hodgkin lymphoma. Particularly PD-1 blockade with nivolumab and pembrolizumab has demonstrated significant single-agent activity in this select population.
Keywords		Hodgkinov limfom imunska nadzorna mesta zaviralci nadzornih stikal inhibitorji učinkovitost toksičnost Hodgkin¼s lymphoma immune checkpoint inhibitors effectiveness toxicity